[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
..
Publication Charge
►Publication Fee
..
In Press
 In Press Articles
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 14, Issue 1 (Winter 2023) ::
Caspian J Intern Med 2023, 14(1): 47-52 Back to browse issues page
Resistance to Single-agent Chemotherapy for Low-risk Gestational Trophoblastic Neoplasia
Shahrzad Sheikhhasani , Aghdas Abdolrazaghnejad , Azam sadat Mousavi , Setareh Akhavan , Narges Zamani , Elham Feizabad
Department of Oncologic Gynecology, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran , dr.abdolrazaghnejad.gynecologist@gmail.com
Abstract:   (1359 Views)
Background: Methotrexate (MTX) and actinomycin D (ActD) have been used as first-line chemotherapy agents in the treatment of low-risk gestational trophoblastic neoplasia (GTN). Although low-risk GTN is considered a curable disease, its reported primary remission rates of 49 to 93% reflect the difficulties of treatment and different factors influencing it. Hence, this study aimed to determine the remission rates and related factors of single-agent chemotherapy resistance in low-risk GTN patients.
Methods: This retrospective study included patients with diagnosed low-risk GTN who received either MTX once a week (IM, 30mg/m2) or ActD once every two weeks (pulsed IV, 1.25mg/m2). Then, the patients were followed-up until complete remission or single-agent treatment failure to assess resistance rate and related factors.  
Results: Eighty-four patients were included in the study (18 patients were receiving MTX and 66 patients were receiving ActD). 85.7% of all participants achieved complete remission after first-line chemotherapy (72.2% in MTX vs 89.4% in ActD). There was a significant association for higher tumor size (P=0.046), the occurrence of metastasis (P=0.019), and pretreatment β-HCG levels (P=0.005) with resistance to treatment.
Conclusion: This study demonstrated higher tumor size, the occurrence of metastasis, and pretreatment β-HCG levels have been associated with increased resistance to first-line chemotherapy agents.
Keywords: Single-agent chemotherapy, Gestational trophoblastic neoplasia, Dactinomycin, Methotrexate, Treatment failure
Full-Text [PDF 292 kb]   (412 Downloads)    
Type of Study: Original Article | Subject: Oncology
Received: 2021/12/29 | Accepted: 2022/02/13 | Published: 2023/01/11
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sheikhhasani S, Abdolrazaghnejad A, Mousavi A S, Akhavan S, Zamani N, Feizabad E. Resistance to Single-agent Chemotherapy for Low-risk Gestational Trophoblastic Neoplasia. Caspian J Intern Med 2023; 14 (1) :47-52
URL: http://caspjim.com/article-1-3295-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 1 (Winter 2023) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.05 seconds with 40 queries by YEKTAWEB 4642